SEC Info℠ | Home | Search | My Interests | Help | Sign In | Please Sign In | ||||||||||||||||||||
12/12/23 |
| ARCH Venture Fund VIII Overage, L.P. |
---|
• | List all Filings as Group Member |
• | Search Recent Filings (as Group Member) for “Arch Venture Fund VIII Overage, L.P.” |
As Of | Filer | Filings # Latest | Issuer (Primary) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
5/13/24 |
| ARCH Venture Fund VIII, L.P. | 9 | SC 13G/A |
| Q32 Bio Inc. | |||||
12/15/23 |
| ARCH Venture Fund XII, L.P. | 2 | SC 13D/A |
| Neumora Therapeutics, Inc. | |||||
2/11/22 |
| ARCH Venture Fund VII, L.P. | 7 | SC 13G/A |
| Unity Biotechnology, Inc. | |||||
2/2/21 |
| Arch Venture Fund VI LP | 4 | SC 13G/A |
| Quanterix Corp. |
As Of | Issuer | Filings # Latest | With Filer (Primary) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
5/13/24 |
| Q32 Bio Inc. | 3 | SC 13G/A |
| ARCH Venture Fund VIII, L.P. | |||||
12/15/23 |
| Neumora Therapeutics, Inc. | 2 | SC 13D/A |
| ARCH Venture Fund XII, L.P. | |||||
9/20/22 |
| Codiak BioSciences, Inc. | 2 | SC 13D |
| ARCH Venture Fund VIII, L.P. | |||||
2/11/22 |
| Unity Biotechnology, Inc. | 4 | SC 13G/A |
| ARCH Venture Fund VII, L.P. | |||||
2/2/21 |
| Metacrine, Inc. | 1 | SC 13G |
| ARCH Venture Fund VIII, L.P. | |||||
2/2/21 |
| Twist Bioscience Corp. | 3 | SC 13G/A |
| ARCH Venture Fund VII, L.P. | |||||
2/2/21 |
| Quanterix Corp. | 4 | SC 13G/A |
| Arch Venture Fund VI LP | |||||
3/6/19 |
| Sienna Biopharmaceuticals, Inc. | 3 | SC 13D |
| ARCH Venture Fund VIII, L.P. |
As Of | Group Member | Filings # Latest | With Filer (Primary) | Issuer (Primary) | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
5/13/24 |
| ARCH Venture Partners VIII, L.P. | 9 | SC 13G/A |
| ARCH Venture Fund VIII, L.P. |
| Q32 Bio Inc. | |||||||
| ARCH Venture Partners VIII, LLC. | 22 | |||||||||||||
| Clinton Bybee | 21 | |||||||||||||
| Keith Crandell | 21 | |||||||||||||
| Robert Nelsen | 21 | |||||||||||||
12/15/23 |
| Arch Venture Fund VII, L.P. | 2 | SC 13D/A |
| ARCH Venture Fund XII, L.P. |
| Neumora Therapeutics, Inc. | |||||||
| Arch Venture Fund X Overage, L.P. | 3 | |||||||||||||
| Arch Venture Fund X, L.P. | 2 | |||||||||||||
| ARCH Venture Partners VII, L.P. | 9 | |||||||||||||
| ARCH Venture Partners VII, LLC | 9 | |||||||||||||
| ARCH Venture Partners X Overage, L.P. | 3 | |||||||||||||
| ARCH Venture Partners X, L.P. | 2 | |||||||||||||
| ARCH Venture Partners X, LLC. | 3 | |||||||||||||
| ARCH Venture Partners XII, L.P. | 2 | |||||||||||||
| ARCH Venture Partners XII, LLC | 2 | |||||||||||||
| Kristina Burow | 3 | |||||||||||||
| Steven Gillis | 3 | |||||||||||||
2/2/21 |
| ARCH Venture Partners VI, L.P. | 4 | SC 13G/A |
| Arch Venture Fund VI LP |
| Quanterix Corp. | |||||||
| ARCH Venture Partners VI, LLC | 4 |